Segment Reporting (Tables)

3 Months Ended

Mar. 31, 2026

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment

	Three Months Ended March 31,
	2026		2025
	(in thousands)
Revenue	$	179,126	$	1,764
Less:
Imdusiran clinical development expense	891		2,171
AB-101-001 clinical development expense	526		1,899
Other research and development expense	2,703		4,889
General and administrative expense	5,889		5,832
Restructuring expense	—		12,373
Other segment expense (1)	237		323
Add:
Interest income	815		1,197
Segment net income (loss)	$	169,695	$	(24,526)
Adjustments and reconciling items	—		—
Consolidated net income (loss)	$	169,695	$	(24,526)

(1) Other segment expense includes the change in the fair value of contingent consideration, non-cash interest expenses and foreign currency exchange gains and losses.